Sanofi to Acquire Dynavax, Expanding Vaccine Portfolio

Sanofi announced its plan to acquire Dynavax Technologies Corporation, known for its adult hepatitis B vaccine HEPLISAV-B® and a shingles vaccine candidate. The $2.2 billion cash deal bolsters Sanofi’s adult immunization offerings. HEPLISAV-B®, marketed in the US, offers faster seroprotection with its two-dose regimen compared to traditional three-dose vaccines.

The acquisition includes the phase 1/2 shingles vaccine candidate, Z-1018. Sanofi aims to leverage its global reach to maximize the impact of Dynavax's products, addressing significant public health needs such as hepatitis B and shingles, prevalent in millions of adults, particularly those unvaccinated before 1991.

This move is aligned with Sanofi’s commitment to provide comprehensive vaccine solutions. The transaction is expected to conclude by the first quarter of 2026, pending regulatory approvals.